Verinurad
 | |
| Clinical data | |
|---|---|
| Other names | RDEA-3170; RDEA3170 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H16N2O2S |
| Molar mass | 348.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.[1][2][3]
References[edit]
- ^ Johansson, Susanne; Han, David; Hunt, Thomas; Björck, Karin; Florica, Delia; Gillen, Michael; Hall, Jesse; Erlandsson, Fredrik (June 2022). "Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants". Pharmacology Research & Perspectives. 10 (3): e00929. doi:10.1002/prp2.929. PMC 9121888. PMID 35593744.
- ^ Fitz-Patrick, David; Roberson, Kent; Niwa, Kiyoshi; Fujimura, Takabumi; Mori, Koji; Hall, Jesse; Yan, Xiaohong; Shen, Zancong; Liu, Sha; Ito, Yasushi; Baumgartner, Scott (2 November 2019). "Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials". Modern Rheumatology. 29 (6): 1042–1052. doi:10.1080/14397595.2018.1538003. PMID 30334639. S2CID 52988677.
- ^ Tan, Philip K.; Liu, Sha; Gunic, Esmir; Miner, Jeffrey N. (6 April 2017). "Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout". Scientific Reports. 7 (1): 665. Bibcode:2017NatSR...7..665T. doi:10.1038/s41598-017-00706-7. ISSN 2045-2322. PMC 5429603. PMID 28386072.